Skip to main content
Premium Trial:

Request an Annual Quote

Pressure Bio Gets $1.2M from Exercise of Warrants

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Pressure BioSciences today said that it has raised $1.2 million from the exercise of preferred stock purchase warrants.

The firm said that 98,372 15-month preferred stock purchase warrants were exercised, representing 100 percent of all outstanding and unexercised 15-month warrants that could be exercised after the March 30, 2010 warrant call.

On March 30, Pressure Bio exercised its right to call all outstanding and unexercised 15-month warrants to purchase shares of the company's Series A convertible preferred stock. Each 15-month warrant was exercisable for preferred stock at an exercise price of $12.50 per share.

Pressure Bio said that the proceeds of $1.2 million were in addition to the $241,625 the firm had previously received from the voluntary exercise of 15-month warrants between November 2009 and March 30, 2010.

In Wednesday afternoon trade on the Nasdaq, shares of Pressure Bio were up 4 percent at $1.82.

The Scan

US Booster Eligibility Decision

The US CDC director recommends that people at high risk of developing COVID-19 due to their jobs also be eligible for COVID-19 boosters, in addition to those 65 years old and older or with underlying medical conditions.

Arizona Bill Before Judge

The Arizona Daily Star reports that a judge is weighing whether a new Arizona law restricting abortion due to genetic conditions is a ban or a restriction.

Additional Genes

Wales is rolling out new genetic testing service for cancer patients, according to BBC News.

Science Papers Examine State of Human Genomic Research, Single-Cell Protein Quantification

In Science this week: a number of editorials and policy reports discuss advances in human genomic research, and more.